Pemphigus is a rare and blistering autoimmune skin dermatosis resulting in significant morbidity and mortality. The treatment of Pemphigus consists of various systemic immunosuppressive agents, which contribute to significant morbidity and mortality in their own regard. Ideally, the risks of immunosuppressive treatment should be outweighed by their benefits in improving and preventing mucocutaneous blistering and ulceration. However, adverse effects of systemic immunosuppression given for the treatment of Pemphigus may cause significant detriment to a patient’s quality of life in addition to the distress caused by their Pemphigus in the first instance. The Department of Dermatology at the Royal Melbourne Hospital has continuously provided a tertiary treatment facility for the management of this rare, autoimmune blistering dermatosis. This study aims to evaluate the quality of care provided to Pemphigus patients at this treatment facility over the past 5 years, and evaluate how the treatments provided have affected the patient’s quality of life.